SEATTLE, Oct. 6 /PRNewswire-FirstCall/ -- Dendreon Corporation (Nasdaq:
DNDN) will host a conference call today, Monday, October 6, 2008 at 9:00 AM
ET (6:00 AM PT) to review the outcome of the interim analysis of its IMPACT
(IMmunotherapy for Prostate AdenoCarcinoma Treatment, also known as D9902B)
clinical trial of PROVENGE(R) (sipuleucel-T), the Company's investigational
active cellular immunotherapy for the treatment of advanced prostate
Those interested may access the call with the following information:
Time: 9:00 AM ET/6:00 AM PT
Date: October 6, 2008
Dial-in: 1-877-419-6598 (domestic) or +1-719-325-4935 (international)
Webcast: http://www.dendreon.com (homepage and investor relations section)
A recorded rebroadcast will be available for interested parties unable to participate in the live conference call by dialing 888-203-1112 or 719-457- 0820 for international callers; the conference ID number is 5304314. The replay will be available from 2:00 pm ET on Monday, October 6, 2008 until midnight ET on Wednesday, October 8, 2008. In addition the webcast will be archived for on-demand listening for 30 days at http://www.dendreon.com.
Dendreon Corporation is a biotechnology company whose mission is to target cancer and transform lives through the discovery, development and commercialization of novel therapeutics. The Company applies its expertise in antigen identification, engineering and cell processing to produce active cellular immunotherapy product candidates designed to stimulate an immune response. Dendreon is also developing an orally-available small molecule called Trp-p8 that could be applicable to multiple types of cancer as well as benign prostatic hyperplasia. The Company has its headquarters in Seattle, Washington and is traded on the Nasdaq Global Market under the symbol DNDN. For more information about the Company and its programs, visit http://www.dendreon.com.
|SOURCE Dendreon Corporation|
Copyright©2008 PR Newswire.
All rights reserved